IGMPI India

China Biologic Products is a fully integrated plasma-based biopharmaceutical company in China. The products of the company are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. The company is headquartered in Beijing and manufactures around 20 plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. China Biologic sells its products to hospitals and other healthcare facilities in China.

Recently, the company has announced its Good manufacturing practice (GMP) certification from China Food and Drug Administration ("CFDA") in respect of its plasma production facility at its Guizhou subsidiary.

The chairman of the company said that they are delighted to receive GMP certification earlier than expected, allowing them to resume full-scale commercial production in late March for all of the approved plasma products, including the newly approved human prothrombin complex concentrate ("PCC"). This concludes the efforts of the past nine months to achieve full compliance with GMP standards at Guizhou facility. This achievement is attributed to the massive contributions of Guizhou employees, who completed comprehensive facility upgrading ahead of schedule. Higher growth is expected with more products available for sales starting in the third quarter this year, due to lag effects from long production cycles and CFDA approval procedures for each batch of products.